Novavax Inc (NVAX)
$16.39
0.00 (0.00%)
NVAX Stock Quote Delayed 30 Minutes
Novavax Stock Looks Volatile As Vaccine Enthusiasm Wanes
And, even with the NanoFlu catalyst serving as a backup, it may not be enough to shore up NVAX stock if its Covid-19 vaccine falls short of expectations. With all this uncertainty at play, tread carefully with NVAX stock.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
1.22B
PE Ratio
-5.12
EPS
-3.2
Volume (Avg. Vol.)
1,785
Day's Range
-
52-Week Range
$3.53 - $23.86
Dividend & Yield
N/A (N/A)
NVAX Stock Predictions, Articles, and Novavax Inc News
Novavax Is Incredibly Risky but Worth a Small Allocation
There's a lot riding on Novavax's novel coronavirus vaccine candidate, making NVAX stock a biotech lottery ticket for bold traders.
Covid-19 Therapeutics May Push Novavax Out of the Spotlight
Novavax has used its 15 minutes of fame to great success. But unless its Covid-19 vaccine launches soon, NVAX stock is set to decline.
Don’t Heed The Bearish Calls and Invest in Novavax
Expect NVAX stock to exceed the $200 mark with two solid growth catalysts in its Covid 19 and Nanoflu vaccine
If You’re Placing Bets on Vaccine Winners, Novavax Ought to Be on Your List
Novavax got a manufacturing partner in mid-September to make 2 billion doses. Despite NVAX stock going sideways since then, it remains a buy.
The Deep Price Pullback Is Your Signal to Buy Novavax
The coronavirus vaccine race is heating up and if you're looking for a potential winner, then now is the time to consider NVAX stock.
The Small-Cap Tech Stocks Tripping My Moneyball ‘Buy’ Alerts
Louis Navellier zeroes in on eventual stock winners, spots their key momentum levers, and allows smart folks to learn how to get positioned months or even years before the mainstream media finally catches on.
The Real Value in Novavax Goes Beyond the Coronavirus
NVAX stock is up over 2,000% on hopes it will deliver a vaccine for the novel coronavirus. However, the real value comes from its influenza vaccine.
Novavax Gains With Start of Phase 3 Vaccine Trial
The announcement of a Phase 3 vaccine trial in the United Kingdom keeps Novavax in contention and shares NVAX stock on investors’ radar.
Deep Diving the Complex Narrative Behind Novavax
With new competition joining the fray in the Covid-19 vaccine race, NVAX stock looks vulnerable. However, the enormous complexity of this arena gives Novavax a fighting chance.
Novavax Stock Definitely Is Not the Long-Shot Vaccine Play You Might Think
Bottom line: don't bet the ranch, but NVAX stock is a buy as it enters Phase 3 trials.
NVAX Stock: Novavax Rallies After Entering Phase 3 Vaccine Trials
Novavax is moving ahead with Phase 3 trials in the United Kingdom, and NVAX stock is rallying higher on the news.
Novavax Is Still Close to Vaccine Leaders in the Covid-19 Race
NVAX stock is goign to be even more interesting in the next two months. Capacity has risen, and study progress has been made.
Keep An Eye On Novavax, But Keep Your Money In Your Pocket
NVAX stock has soared as investors watch its progress on a coronavirus vaccine. But it's not even the front-runner and remains unprofitable.
Novavax Investors Betting They Have the COVID-19 Solution
Novavax has gotten $2 billion in support from the government, and is rushing its COVID-19 vaccine candidate through trials, hoping its adjuvant makes for fast distribution.
Novavax Stock Is a Solid Bet on Vaccine Hopes
The case for NVAX stock is simple: vaccine approval should lead to a significant rally. With progress continuing and the stock cheaper, that case holds.
Why the Perplexing Science of Vaccines Keeps Novavax Around
Though Novavax is behind in the clinical trial race, that doesn’t necessarily mean NVAX stock is done for. However, investors who want to take a bet must do so very carefully.
Novavax Stock Is a Risky Way to Get Rich Quick
Unless you have a deep understanding of drug development, buying NVAX stock on hopes it will win the vaccine race is risky.
The Upside Potential Of Novavax Is Hard To Ignore
With the Novavax share price running higher again, now might be the time for investors to ride NVAX stock to lucrative gains.
